A Phase 1, First-in-human Study of VX-433

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-433 following single and multiple ascending doses, as well as to assess the effect of VX-433 on the PK of midazolam, bupropion, and hydroxybupropion.
Epistemonikos ID: f89001d1d7dfd692cb23aa03f621522da4508a21
First added on: May 14, 2026